Sharps Technology, Inc. Announces Closing of $16 Million Initial Public Offering

Rhea-AI Summary

Sharps Technology, Inc. (NASDAQ: STSS, STSSW) has successfully closed its initial public offering of 3,750,000 units, priced at $4.25 each, generating approximately $16 million in gross proceeds. Each unit comprises a share of common stock and two warrants, with an exercise price of $4.25. The offering saw the underwriter exercise an over-allotment option for 1,125,000 warrants. The common stock and warrants began trading on Nasdaq on April 14, 2022. Aegis Capital Corp. managed the offering, which was declared effective by the SEC on April 13, 2022.

Positive

• Raised approximately $16 million in gross proceeds from the IPO.
• Expanded market presence with shares and warrants now trading on Nasdaq.

Negative

• Potential dilution of existing shareholders due to the issuance of 3,750,000 shares and additional warrants.
• Market perception of warrants may lead to volatility in stock price.

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of 3,750,000 units at a public offering price of $4.25 per unit. Each unit consisted of a share of common stock and two warrants to purchase one share of common stock each with an exercise price of $4.25. The underwriter partially exercised its over-allotment option with respect to 1,125,000 warrants. At the closing, the Company issued an aggregate of 3,750,000 shares of common stock and 8,625,000 warrants. Gross proceeds for the offering were approximately $16 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The common stock and warrants began trading on The Nasdaq Capital Market on April 14, 2022, under the symbols “STSS” and “STSSW,” respectively.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

A registration statement on Form S-1 (No. 333-263715) relating to the securities sold in this offering was declared effective by the Securities and Exchange Commission (the “SEC”) on April 13, 2022. The offering is being made only by means of a prospectus. Copies of the final prospectus are available on the SEC’s website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction

About Sharps Technology, Inc.

Sharps Technology, Inc. is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps Provensa™ is the Company’s premier line of smart safety syringes that eliminate accidental needlestick injuries, prevent needle reuse, and reduce wasted medicine and vaccines—while retaining the intuitive simplicity of traditional syringes. Please visit SharpsTechnology.com to learn more.

Forward-Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact:
Dave Gentry
Phone Number: +1 407-491-4498
Email: dave@redchip.com 

FAQ

What are the details of Sharps Technology's initial public offering?

Sharps Technology closed its IPO of 3,750,000 units at $4.25 each, generating about $16 million in gross proceeds. Each unit includes shares of common stock and warrants.

When does trading for STSS and STSSW shares begin?

Trading for the common stock (STSS) and warrants (STSSW) began on April 14, 2022.

Who managed Sharps Technology's IPO?

Aegis Capital Corp. acted as the sole book-running manager for Sharps Technology's IPO.

What risks are associated with the new shares issued by Sharps Technology?

The issuance of new shares may lead to dilution for existing shareholders, affecting their ownership percentage and potentially impacting stock price.